About Urotronic
Urotronic is a company based in Plymouth (United States) founded in 2015 was acquired by Laborie Medical in September 2023.. Urotronic has raised $47.05 million across 4 funding rounds from investors including Laborie Medical, Legend Capital and CD Capital. Urotronic offers products and services including Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems. Urotronic operates in a competitive market with competitors including Neotract, Butterfly Medical, Zenflow, Rivermark and ProVerum Medical, among others.
- Headquarter Plymouth, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Urotronic Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$47.05 M (USD)
in 4 rounds
-
Latest Funding Round
$954.36 K (USD), Series C
Oct 20, 2020
-
Investors
Laborie Medical
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Laborie Medical
(Sep 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Urotronic
Urotronic offers a comprehensive portfolio of products and services, including Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Device for treating benign prostatic hyperplasia.
Balloon for anterior urethral stricture therapy.
System for wireless reflux monitoring.
Tools for assessing urinary function.
Unlock access to complete
Funding Insights of Urotronic
Urotronic has successfully raised a total of $47.05M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $954.36 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $954,360
-
First Round
First Round
(06 Jul 2018)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Series C - Urotronic | Valuation |
investors |
|
| Oct, 2020 | Amount | Series C - Urotronic | Valuation | Laborie Medical |
|
| Aug, 2018 | Amount | Series B - Urotronic | Valuation | HM Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Urotronic
Urotronic has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Laborie Medical, Legend Capital and CD Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Healthcare venture capital investments are managed by HM Venture Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Urotronic
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Urotronic
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Urotronic Comparisons
Competitors of Urotronic
Urotronic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neotract, Butterfly Medical, Zenflow, Rivermark and ProVerum Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Minimally invasive devices in urology
|
|
| domain | founded_year | HQ Location |
Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH)
|
|
| domain | founded_year | HQ Location |
A device is developed to treat urinary obstruction from BPH.
|
|
| domain | founded_year | HQ Location |
Medical device for benign prostatic hyperplasia treatment is developed.
|
|
| domain | founded_year | HQ Location |
Developer of a minimally-invasive medical device for benign prostatic hyperplasia
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Urotronic
Frequently Asked Questions about Urotronic
When was Urotronic founded?
Urotronic was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is Urotronic located?
Urotronic is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Who is the current CEO of Urotronic?
David Perry is the current CEO of Urotronic.
Is Urotronic a funded company?
Urotronic is a funded company, having raised a total of $47.05M across 4 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Jul 06, 2018.
What does Urotronic do?
Urotronic was founded in 2015 and is based in Plymouth, United States. Operations center on the medical device sector, specifically urological applications. A urethral device known as the Optilume drug-coated balloon has been created for stricture treatment. Balloon dilation is combined with drug delivery technology, where paclitaxel uptake is employed to restrict cell proliferation and fibrotic scar tissue formation, addressing recurrence issues.
Who are the top competitors of Urotronic?
What products or services does Urotronic offer?
Urotronic offers Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems.
Who are Urotronic's investors?
Urotronic has 4 investors. Key investors include Laborie Medical, Legend Capital, CD Capital, and HM Venture Partners.